STTK

Shattuck is a pre-commercial clinical-stage biotech, and its financials behave exactly like one: FY2025 'revenue' of $1.00M is collaboration/other income (down 82.5% and bouncing between $0.65M and $5.72M over five years), so the 504x P/S and -4,880% net margin are meaningless — the entire equity story rests on one asset, SL-325, a DR3-blocking antibody now finishing a healthy-volunteer Phase 1 (completion expected Q2 2026) with a Crohn's Phase 2 slated to start Q3 2026. The 10-K states plainly the company is 'substantially dependent on the success of our lead product candidate, SL-325' and 'may never achieve or maintain profitability.' This is a binary, single-shot bet, not an investable business on fundamentals.

The balance sheet is clean but shallow. Liabilities/equity is just 0.10x and there is no meaningful debt, but cash of $54.2M against an operating cash burn of -$39.9M implies only ~1.3–1.4 years of runway. Management explicitly warns it 'will require additional funding' and that raising it 'may cause dilution to our existing stockholders' — and dilution is already underway: shares outstanding jumped 49.4% YoY to 71.6M. A financing before or shortly after Phase 2 initiation is close to a certainty, and it will land while the stock's fate hangs on unblinded early data. The narrowing net loss (-$48.8M, +35.3% YoY) and 47.5% cut to R&D reflect belt-tightening between programs, not operating leverage.